Range
2.65 - 2.83
Vol / Avg.
1.1M/1.2M
Div / Yield
-
52 Wk
0.73 - 3.13
Mkt Cap
454M
Payout Ratio
-
Open
2.65
P/E
-
EPS
0.01
Shares
162.1M
Outstanding
162.1M
Total Float
120.7M
load more
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for acute spinal cord injuries and VAC2, a allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer. Its lead cell delivery clinical program is Renevia, an investigational medical device developed as an alternative for whole adipose tissue transfer procedures.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-08-05
REV
Q1 2021Est.ActualSurprise
EPS-0.040-0.010 0.0300
REV790.000K391.000K-399.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
LCTXLineage Cell Therapeutics-0.36%454M

Lineage Cell Therapeutics Frequently Asked Questions

Q

How do I buy Lineage Cell Therapeutics (LCTX) stock?

A

You can purchase shares of Lineage Cell Therapeutics (AMEX: LCTX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Lineage Cell Therapeutics's (LCTX) competitors?

A

There are no as such competitors for Lineage Cell Therapeutics.

Q

What is the target price for Lineage Cell Therapeutics (LCTX) stock?

A

The latest price target for Lineage Cell Therapeutics (AMEX: LCTX) was reported by Cantor Fitzgerald on March 31, 2021. The analyst firm set a price target for 6.00 expecting LCTX to rise to within 12 months (a possible 114.29% upside). 2 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Lineage Cell Therapeutics (LCTX)?

A

The stock price for Lineage Cell Therapeutics (AMEX: LCTX) is $2.8 last updated Today at 7:59:51 PM.

Q

Does Lineage Cell Therapeutics (LCTX) pay a dividend?

A

There are no upcoming dividends for Lineage Cell Therapeutics.

Q

When is Lineage Cell Therapeutics (AMEX:LCTX) reporting earnings?

A
Lineage Cell Therapeutics’s Q2 earnings are confirmed for after-market on August 5, 2021.
Q

Is Lineage Cell Therapeutics (LCTX) going to split?

A

There is no upcoming split for Lineage Cell Therapeutics.

Q

What sector and industry does Lineage Cell Therapeutics (LCTX) operate in?

A

Lineage Cell Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the AMEX.